logo-loader

ImmuPharma PLC

Receive alerts
Market:
AIM
Market Cap:
£12.55 m
Price
7.50 GBX
Change
-2.60%
52 weeks high
18.50
52 weeks low
7.33

In brief

ImmuPharma PLC is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by

High unmet medical need

Low marketing costs

Relatively low development costs

Founded first in Basel, Switzerland in 1999 and led by an experienced management team, ImmuPharma now has important R&D collaboration arrangements with highly respected health and medical research laboratories in Europe. The company plans either to bring its drug candidates to market itself, or to license them in corporate deals to other pharmaceutical companies.

Deep dive We explore the investor case for growth companies

Snapshot

  • Flagship drug is Lupuzor, a treatment for lupus
  • 'Follow-up' study confirmed outstanding safety profile
  • Nucant cancer treatment also going through the clinic